Great, thanks for the summary....200p+ in a takeover |
Yep - Canaccord think so too:
We update our forecasts for the revised FY24 guidance and raise our FY25 revenue and adj. EBIT forecasts by 5% and 11%, respectively, to reflect the strong growth outlook and steady increase in operational gearing.
On a CY25E EV/Sales of 2.7x, Diaceutics trades at a ~25% discount to peers despite its superior organic sales trajectory (two-year CAGR 25% vs 16% peer group average), improving revenue visibility and profitable horizon. We raise our TP to 180p (from 160p), equivalent to a CY25E of 3.5x on our new forecasts, in line with the peer group average. |
Solid update........... |
Yes melody sweet set up here for DXRX , a lot of revenues in dollars , a lot of costs are in pounds , and service business that can't be hit by tariffs . |
90% of biz from US benefiting from strength of US$ / weakness of £ |
Interesting move today and probably gives you a clue as to where the future owner of this business is based.......... |
Took an initial position today. Looks an interesting company. |
Hoping for a good 25' with this one........ |
Nice prompt update from West Elk.... only 9 months after the event :)
Regards To All
Mr D |
Nice contract news....... |
I spy with my little eye... |
big trade just printed at mid.......also Gresham have been topping up |
Who is likely to take this over..? |
melody, no reduction, have a listen to this interview with Peter, who was the previous CEO and still a significant holder.
A friend and fellow investor reminded me of this recently and said "Just listened to this again from March 2023 so nearly 18 months ago. Peter Keeling talks of 180 lab network, now around 1000 and really pleased that Signal was as good as 3 or 4 days, now daily in the US. Incredible progress in a short period of time." |
Thanks MG ...reduction in labs then from 2.5 to 1K?
Obviously the platform is the key attribute - I'd like to gain some more insight into the revenue modeland the moat....what is it that is most attractive to customers.
I'll look in at Investor Meet. |
melody, they have around 1000 labs now. I would suggest you look at the latest IMC presentation they did after the results. That should put you up to speed with where they are now. Their offering 'Signal' has been better received than I expected and the contracts coming in now (like the latest one) also suggest that they may be developing further revenue streams.
ATB
@MGinvestor |
Certainly at a point of at least a 75-80% holdings reduction ought to be completed anyway |
It may tank after this week. Would take a big rise today to stop it |
Some serious reductions and distribution |
Triple Top |
Smithie - I've just done a little digging here too.
DXRX is providing a precision medicine platform - The Diagnostics Network (TDN). It gathers info from over 2500 labs - allowing access to pharma / biotech to obtain data and to collaborate.
What is precision medicine? Looked up and defined as treatment using information about a person's genes, proteins, environment, and lifestyle. I doubt TDN is patient based - from the schematic it looks disease / research based
Scroll down this page for a useful schematic:
Have a look at this video
Any current investors ... please correct me if my understanding is wrong. |
Buyers back here after the slight pullback....... |
 Smithie
they source actionable data from a wide network of labs and inform pharma companies and physicians when there is an opportunity to deploy some of their expensive and specific drugs, I think
for example for Non small cell lung cancer, NSCLC the therapy depends on the cellular expression of Epidermal growth factor and/or a number of others, some of which are more prevalent in certain ethnic groups.
for breast cancer, ER, PR, Her2 are the common cellular antigens tested for and can be strongly positive, weakly expressed or absent,status of each can change during the course of the disease, new drugs available now for weakly expressing Her2 and ER so much more nuanced than previously,
Neuroendocrine tumours depend on Ki1
Lymphomas -treatment depends on a wide variety of cellular markers some demanding eg no immediate treatment others btk therapy and cytogenetics which are deemed favourable or unfavourable, the latter demanding more intensive therapy or bone marrow transplant
thyroid, NTRK or RET, calcitonin,
renal tumours combinations of Ck7 and others for different types with very variable prognosis and treatment
stomach and increasingly other sites, her2
prostate recurrence reappearance of PSA often first indication
their main market should be US as the health system there is much less integrated than, for instance, the NHS where cancer patients should be put through hospital formal meetings where all this is discussed,
citrullinated antibody positivity might be first indication of rheumatoid etc
I think this is what they do, others correct me if I'm mistaken! |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
